Autopsy report · NCT05207371

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

“Decision based on the development company's development policy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 3 months before it stopped.
• 22 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

GAIA BioMedicine Inc.

Sponsor type

Industry

Conditions

Cell Therapy; NSCLC

Interventions

Biological

Participants

22

Sites

3

Countries

Japan

Trials that died the same way

• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (69% match in meaning)
• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
  “company development strategy adjustment” (67% match in meaning)
• Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS
  “Change in development plan” (64% match in meaning)
• Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
  “Business decision not to continue development” (64% match in meaning)
• A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
  “Development plan change” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.